Omalizumab in idiopathic anaphylaxis.
Priya
P
Warrier
Thomas B
TB
Casale
D000485:Allergens / Q000276:immunology; D000707:Anaphylaxis / Q000150:complications / Q000276:immunology / Q000628:therapy*; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D002648:Child; D005512:Food Hypersensitivity / Q000150:complications / Q000276:immunology; D005541:Forced Expiratory Volume / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood / Q000276:immunology; D008297:Male; D000069444:Omalizumab; D012130:Respiratory Hypersensitivity / Q000150:complications / Q000628:therapy; D012882:Skin Tests
D000485:Allergens; D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D007073:Immunoglobulin E